FDA-Registered · DEA-Licensed · cGMP Compliant

Pharmaceutical
Manufacturing Built
for What's Next

Belleview Bioscience is a full-service pharmaceutical contract manufacturer serving OTC and Rx markets from our Brooksville, Florida facility. We produce finished dosage forms that meet the highest standards of safety, compliance, and consistency.

295K+
Tablets/hr Capacity
4,200L
Liquid Capacity
17+
Product SKUs
Scroll
DUNS 131968803 · FDA Registered
FEI 3005350897 · FDA Establishment
DEA RW9633760 · Schedule II, IV, V
FL DBPR 28101 · 20442 · 21912
DSCSA Serialization Compliant

Who We Are

Your Partner in Pharmaceutical Manufacturing

Belleview Bioscience operates a state-of-the-art cGMP manufacturing facility in Brooksville, Florida — producing oral liquids, solid dose tablets, and unit dose products for healthcare institutions, pharmaceutical partners, and national distributors.

💊
Solid Dose Manufacturing
Three high-speed tablet presses producing up to 295,500 tablets per hour across OTC and Rx formulations.
🧪
Liquid Manufacturing & Filling
4,200L combined liquid capacity with a 6-head filler handling 30mL–946mL volumes for oral solutions and suspensions.
📦
Unit Dose & Packaging
Two solid dosage packaging lines producing 13,500+ (100ct) bottles per day, plus blister packaging capabilities.
cGMP
Compliance-First Manufacturing
Every process, every product, every batch — built around FDA compliance, DSCSA serialization, and the rigorous standards our customers and their patients depend on.
Serving Partners Across the Pharmaceutical Spectrum
NDA Product Holders
ANDA Filers & Generics
505(b)(2) Developers
Hospital & IDN Networks
GPO Formulary Partners
Industrial Health Programs
National Distributors
Specialty Pharma Companies

Ready to Partner

Start a Conversation

Whether you need CMO manufacturing, ANDA product supply, or unit dose packaging — we're ready to discuss your needs.

What We Do

Manufacturing
Capabilities

Full-spectrum pharmaceutical contract manufacturing — oral liquids, solid dose, and unit dose packaging — from our FDA-registered, DEA-licensed Brooksville, FL facility.

Solid Dose

Tablet Manufacturing

Three high-speed rotary tablet presses with combined capacity exceeding 295,000 tablets per hour across OTC and Rx formulations.

⚙️
41-Station Double Sided
High-speed double-sided rotary press for maximum throughput on large-volume OTC and Rx tablet runs.
123,000 tablets/hr
⚙️
39-Station Double Sided
Versatile double-sided press optimized for mid-volume production with rapid changeover capability.
117,000 tablets/hr
⚙️
37-Station Single Sided
Single-sided press ideal for specialty tablet formulations and smaller batch production runs.
55,500 tablets/hr

Liquid Manufacturing

Oral Solutions & Suspensions

4,200L combined liquid manufacturing capacity for oral solutions and suspensions with full in-house testing and DSCSA-compliant serialization.

🧪
Primary Liquid Tank
Large-batch liquid manufacturing for high-volume oral solution and suspension production.
3,000L Capacity
🧪
Secondary Liquid Tank
Secondary tank enabling concurrent production runs and formulation changeover flexibility.
1,200L Capacity
🔬
6-Head Liquid Filler
Precision filling for bottles and unit dose containers across a broad volume range.
30mL – 946mL

Packaging

Packaging & Serialization

Full packaging capabilities with DSCSA-compliant 2D barcoding, lot traceability, and serial number generation on all finished products.

📦
Solid Dosage Line A
High-capacity bottling line for solid dose products with integrated serialization and verification.
9,000 (100ct) bottles/day
📦
Solid Dosage Line B
Secondary packaging line providing production redundancy and concurrent run capability.
4,500 (100ct) bottles/day
🗂️
Blister & Unit Dose
Blister packaging and unit dose cup production for hospital, clinic, and first aid applications.
DSCSA Serialized

Coming Soon

Softgel & Gel Tablet Facility

Belleview is adding a dedicated softgel and gel tablet manufacturing facility — purpose-built to expand our dosage form capabilities and support ANDA product development for our pharmaceutical partners.

In Design
💊
Softgel Encapsulation
New 35,000 sq ft facility purpose-built for softgel capsule manufacturing — a high-margin dosage form with strong demand across OTC, Rx, and nutraceutical markets. Designed to support ANDA product development and commercial supply.
35,000 Sq Ft
🔬
Gel Tablet Manufacturing
Gel tablet capability for partners requiring innovative solid dose formats with enhanced bioavailability and patient compliance profiles. Expands Belleview's solid dose portfolio beyond traditional compressed tablets into next-generation dosage forms.
New Dosage Form
📋
ANDA Pipeline Support
The new facility is designed from the ground up to support Abbreviated New Drug Application manufacturing — enabling Belleview to serve as a designated manufacturing site for partners filing ANDAs and 505(b)(2) products in softgel dosage forms.
ANDA Ready
Expansion Timeline

The softgel and gel tablet facility is currently in design phase with an 18–24 month build timeline. Interested partners are encouraged to reach out early to discuss manufacturing agreements and capacity reservations.

Licenses & Registrations

Regulatory Standing

Belleview holds one of the most comprehensive regulatory stacks available to a contract pharmaceutical manufacturer — enabling us to produce virtually any finished dosage form for any market.


DUNS 131968803FDA Registered
FEI 3005350897FDA Establishment
16117920548FDA Food Facility
37218FDA Food Canning

RW9633760Schedule II, IV, V · Listed Chemical
DEA Schedule II–V licensing enables manufacturing of controlled substance products — a rare credential that most contract manufacturers do not hold.

28101Prescription Drug Repackager
20442Prescription Drug Manufacturer
21912OTC Manufacturer

Ready to Discuss Your Project?

Our team is available to discuss your manufacturing requirements, timeline, and regulatory needs.

The People

Our Team

Experienced operators, scientists, and quality professionals — built for regulated pharmaceutical manufacturing.

Belleview Bioscience

Operations Leadership

JR
Justin Ruch
Chief Operating Officer & Partner
Belleview · Kesin Pharma
  • COO across Belleview Bioscience & Kesin Pharma
  • Masters of Public Health — West Virginia University
  • Former QC Manager — Cambrex
  • AR&D Chemist — Catalent & Vista Pharm
MS
Michael Sirianni
Operations Manager
Belleview Bioscience
  • 20+ years in pharma, nutraceutical & food manufacturing
  • Former Associate Operations Manager — General Dynamics
  • Deep expertise in cGMP manufacturing operations & process management
  • Solid dose, liquid manufacturing & packaging operations
AH
Alonzo Harris
Quality Assurance Manager
Belleview Bioscience
  • 8 years regulated pharmaceutical QA experience
  • FDA, DEA, State & Customer audit leadership
  • Built QA departments, SOP libraries & CAPA systems
  • BS — Wayne State University · Published Author
AS
Adam Schoenbaum
Partner
Belleview Bioscience
  • Partner and co-owner of Belleview Bioscience
  • Founder & Owner, Dress the Population — nationally recognized fashion brand
  • Serial entrepreneur with a track record of building consumer brands from the ground up
  • Brings business development, brand strategy, and ownership perspective to the leadership team
Supporting Kesin Pharma's Manufacturing Needs
Belleview Bioscience serves as the dedicated manufacturing partner for Kesin Pharmaceuticals — providing the production capacity, regulatory compliance, and cGMP infrastructure that supports Kesin's large-scale pharmaceutical distribution and growing product portfolio.
DH
David Hernandez
Chief Executive Officer
AB
Andrew Berk
EVP, Business Development

Ownership

Privately Held & Owner-Operated

Belleview Bioscience is privately owned and operated by a dedicated group of investors and entrepreneurs who bring diverse business experience, long-term capital commitment, and a shared belief in the value of domestic pharmaceutical manufacturing.

JR
AS
JS
SC
SE

Ownership Group · Belleview Bioscience

Latest Updates

News & Updates

Recent developments, new partnerships, and milestones from Belleview Bioscience.

● New Partnership
Belleview Enters New Contract Manufacturing Agreement for National First Aid Station Network
Belleview Bioscience has entered into a contract manufacturing agreement to produce unit dose first aid cups and dual action tablets for a national first aid station network — representing 3.6 million sachets annually.
Q2 2026
● NDA Milestone
Belleview Onboards First NDA-Referenced Rx Product
Belleview will manufacture a trimethoprim oral solution under an existing NDA — marking Belleview's first NDA-referenced product and a significant milestone in the transition into branded Rx manufacturing.
Q2 2026
● CMO Partnership
Belleview in Discussions to Expand Oral Liquid CMO Portfolio with Guaifenesin & APAP
A pharmaceutical partner is evaluating Belleview for guaifenesin and acetaminophen bottle production, leveraging Belleview's established 3-year real-time stability data on both products — significantly reducing onboarding timeline.
Q3 2026
● Regulatory
Belleview Pursuing NABP Accreditation — Applying Kesin's Proven Compliance Framework
Belleview Bioscience is actively pursuing NABP accreditation, applying the same quality and compliance frameworks operating at NABP-accredited Kesin Pharmaceuticals. Accreditation will unlock direct formulary access at major health systems.
2026
● Expansion
35,000 Sq Ft Softgel Facility in Design — Target Products Represent $MM+ Revenue Opportunities
Belleview's 35,000 sq ft softgel manufacturing facility is in active design phase, purpose-built to support ANDA product development and 505(b)(2) pipeline manufacturing for Kesin Pharma's commercial distribution network.
2026

Industry Events

Where You'll Find Us

Belleview Bioscience attends key pharmaceutical industry conferences to connect with partners, customers, and the broader CMO community.

June 2–4, 2026
CPHI North America
📍 Philadelphia, PA
North America's leading pharmaceutical ingredients and contract services exhibition. Belleview attends CPHI to connect with ANDA partners, CMO customers, and specialty pharma companies exploring domestic manufacturing relationships.
Business Development
September 2026
Contract Pharma Conference & Expo
📍 New Brunswick, NJ
One of the pharmaceutical industry's leading events focused on contract manufacturing and outsourcing. Belleview will be in attendance to discuss CMO capabilities, ANDA pipeline manufacturing, and oral liquid and softgel production opportunities.
CMO & Outsourcing
Ongoing
Available for Facility Tours
📍 Brooksville, FL
Prospective partners and customers are welcome to visit our Brooksville facility for a first-hand look at our manufacturing capabilities, quality systems, and team. Contact us to schedule a tour at your convenience.
Schedule a Visit

Get In Touch

Contact Us

Whether you're exploring a CMO relationship, have a product to manufacture, or want to learn more about our capabilities — we'd like to hear from you.

Our Facility

Brooksville, Florida

Address
15431 Flight Path Dr
Brooksville, FL 34604
Phone
352-549-9917
Monday–Friday, 8am–5pm EST
Email
Sales@Belleviewbio.com
For manufacturing inquiries, partnership discussions, and general information
Website
Belleviewbio.com
FDA-Registered · DEA-Licensed · cGMP
Belleview Bioscience is fully registered to manufacture OTC and Rx pharmaceutical products for commercial distribution throughout the United States.

Send a Message

Tell Us About Your Needs

We typically respond within one business day. For urgent matters please call 352-549-9917.